Quantitative analysis of onset timing of interstitial lung disease during treatment with biologics

Quantitative analysis of onset timing of interstitial lung disease during treatment with biologics - Onset timing of biologics-related interstitial lung disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015358

Enrollment

Registered

2014-10-09

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Having ICD-10 codes (M05 & M06) for rheumatoid arthritis. 2. Treated with the following biologics; infliximab, tocilizumab, certolizumab pegol, adalimumab, golimumab, etanercept, and abatacept. 3. Having diagnoics codes for interstitial lung diseases after initiation of treatment with the above biologics.

Exclusion criteria

Exclusion criteria: 1. Having diagnostic codes for interstitial lung diseases within 3 days after the treatment initiation. 2. Using anticancer drugs. 3. Under 18-years of age.

Design outcomes

Primary

Measure	Time frame
Onset timing of interstitial lung disease	—

Countries

Japan

Contacts

Public ContactHisashi Urushihara

Keio University Drug Development and Regulatory Science, Faculty of Pharmacy

urushihara-hs@pha.keio.ac.jp03-5400-2649

Outcome results